CoChat

Entinostat: a promising treatment option for patients with advanced breast cancer

Open access
Connolly, Roisin M, Rudek, Michelle A, Piekarz, Richard · 2017 · Future Oncology

The DOI matches its Crossref record; 66 of the 66 references it cites were found in a registry or an index.

Abstract

Entinostat is a synthetic benzamide derivative histone deacetylase (HDAC) inhibitor, which potently and selectively inhibits class I and IV HDAC enzymes. This action promotes histone hyperacetylation and transcriptional activation of specific genes, with subsequent inhibition of cell proliferation, terminal differentiation and apoptosis. This oral HDAC inhibitor has been evaluated in Phase I and II trials in patients with advanced malignancies, and is in general well tolerated. Entinostat does not currently have regulatory approval for clinical use; however promising preclinical and clinical data exist in hormone-resistant breast cancer. An ECOG-ACRIN Phase III registration study is ongoing in advanced breast cancer (E2112, NCT02115282) and aims to confirm the overall survival advantage observed with the combination of exemestane and entinostat/placebo in the Phase II setting (ENCORE301 trial). This article provides an overview of the chemistry, pharmacokinetics/pharmacodynamics and available clinical data for entinostat with a focus on advanced breast cancer.

Overview

Integrity signals

Registry

Crossref · 10.2217/fon-2016-0526

Cites

66 of 66 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Research works printed but not linked: 1

  1. 10.1016/S1470-2045(14)71159-3 · DOI · Paper page

Cited by

See all 150

Metadata

Authors
Connolly, R. M., Rudek, M. A., & Piekarz, R.
Affiliations
  • Sidney Kimmel Comprehensive Cancer Center,Johns Hopkins School of Medicine, Baltimore, MD, USA
  • Johns Hopkins University (US)
  • National Institutes of Health (US)
Venue
Future Oncology
Published
2017-03-09
Volume
13
Issue
13
Pages
1137-1148
ISSN
  • 1479-6694 (ISSN-L)
  • 1744-8301
OpenAlex
W2591958823
Cited by
148
References
66
Citations by year
2026: 12 · 2025: 18 · 2024: 22 · 2023: 22 · 2022: 16 · 2021: 19 · 2020: 15 · 2019: 14 · 2018: 7 · 2017: 3
FWCI
4.35
Type
journal article
Language
en
Open access
Locations
  • Future Oncology (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
Celgene
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Histone Deacetylase Inhibitors Research
  • Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
Keywords
entinostat, histone deacetylase inhibitors, advanced breast cancer, hormone-resistant breast cancer, histone hyperacetylation, benzamide derivatives, pharmacokinetics, pharmacodynamics, anticancer drug development
MeSH terms
Antineoplastic Combined Chemotherapy Protocols, Benzamides, Breast Neoplasms, Female, Humans, Neoplasm Staging, Pyridines, Apoptosis, Epigenesis, Genetic, Cell Line, Tumor, Cell Proliferation, Histone Deacetylase Inhibitors, Drug-Related Side Effects and Adverse Reactions

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.